Asset Manager

Updated:

Hangzhou Heda Industry Fund Investment

Government-backed venture vehicle deploying Qiantang New Area capital alongside LAV and New Alliance Capital into Chinese healthcare and tech.

Hangzhou Heda Industry Fund Investment

Hangzhou Heda Industry Fund Investment functions as the direct investment arm of the Hangzhou Qiantang New Area Industrial Development Group, a government-backed entity responsible for economic growth in one of Zhejiang province's key development zones. While a founding date is not publicly fixed, the firm's mandate consolidates municipal industrial policy with private venture deployment, targeting sectors the Qiantang district has designated as strategic. The firm executes a multi-stage strategy spanning seed, startup, and expansion phases. Its capital is deployed across enterprise software, digital health, industrial technology, and AI-driven platforms, with a geographic focus on China's eastern seaboard. Public record shows it operates in concert with established healthcare and technology investors; it has co-invested alongside Lilly Asia Ventures and New Alliance Capital in pharmaceutical ventures, including rounds for Lynk Pharmaceuticals. The firm also manages assets tied to the Hangzhou Heda Hi-Tech Industrial Park, a physical development zone in Zhejiang. As a government-guided fund, Hangzhou Heda is structurally distinct from independent venture firms: its parentage ties capital deployment decisions directly to the Qiantang New Area Management Committee. The firm is one of several such district-level investment platforms in Zhejiang, reflecting China's dispersed model of state-backed innovation funding. Adjacent vehicles and professional headcount data are not publicly disclosed. What distinguishes Hangzhou Heda is its hybrid posture — it is neither a purely financial LP nor a passive state grantor. It co-invests directly alongside private venture firms in named, competitive life-science deals, merging industrial park development objectives with active minority-position venture investing. This architecture links the operational assets of a government hi-tech park with a risk-taking private-investment mandate, a model mirrored in several advanced Chinese industrial cities but rarely observed by outside allocators.

General information

Firm type

Generalist

Year founded

AUM

Undisclosed

Location

Region

Asia

Country

China

City

Hangzhou

Corporate office

Hangzhou, Zhejiang, China

Sector focus

Enterprise SoftwareDigital HealthAI/MLIndustrial TechMobility & Transportation

Frequently asked questions

Who ultimately controls Hangzhou Heda Industry Fund Investment?

The firm is wholly owned by the Hangzhou Qiantang New Area Industrial Development Group, which in turn is controlled by the Hangzhou Qiantang New Area Management Committee. This makes it a direct instrument of municipal government industrial policy in the Qiantang district of Zhejiang province.

How does Hangzhou Heda source its investments?

The firm operates in close coordination with the Qiantang New Area's economic development mandates and frequently co-invests with established healthcare and technology venture firms. Its sourcing model combines government policy priorities with private deal flow from relationships like those with Lilly Asia Ventures and New Alliance Capital.

Does Hangzhou Heda invest only in companies located in its industrial park?

While the firm manages assets tied to the Hangzhou Heda Hi-Tech Industrial Park, its public co-investments appear to extend beyond park tenants. It has participated in broader pharmaceutical and technology rounds, suggesting a dual mandate of park development and flexible venture deployment across China.

Which sectors does Hangzhou Heda target?

Based on co-investment activity and industrial park focus, confirmed areas include digital health, pharmaceuticals, enterprise software, and industrial technology. The firm's strategy follows the Qiantang New Area's strategic designation of these sectors for economic development.

What is Hangzhou Heda's relationship with Lilly Asia Ventures?

Lilly Asia Ventures appears as a frequent co-investor alongside Hangzhou Heda in healthcare and pharmaceutical rounds, including known positions in Lynk Pharmaceuticals. The relationship provides Hangzhou Heda direct exposure to venture-stage life science deals sourced by an established healthcare specialist.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on family offices?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo